Overview

A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1, non-randomized, sequential-cohort, dose escalation, open-label study designed to evaluate the safety and tolerability of RadProtect® in healthy volunteers. This study is to be conducted at two clinical centers and in conformity with Good Clinical Practice (GCP).
Phase:
Phase 1
Details
Lead Sponsor:
Original BioMedicals Co. Ltd.
Treatments:
Amifostine